Skip to main content

The SURPASS trials: Summarizing efficacy data on tirzepatide

What you need to know

The novel type 2 diabetes medication tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.


Its efficacy is being tested in the phase 3 SURPASS clinical trial program, with results of the cardiovascular outcomes study and a trial of tirzepatide in people with obesity but without diabetes expected in 2024. Explore this page for trial results and expert commentary, updated as new results are reported.

SURPASS-1 trial results & series summary

John Wilding

06-29-2021 | ADA 2021 | Conference coverage | Video

The SURPASS trials so far: Tirzepatide, semaglutide, and type 2 diabetes

John Wilding gives an overview of the SURPASS findings to date, and discusses their importance and how tirzepatide may be used in the clinic.

06-26-2021 | ADA 2021 | Conference coverage | News

SURPASS-1: Tirzepatide has ‘potent’ glucose-lowering and weight loss efficacy

The dual GIP and GLP-1 receptor agonist tirzepatide has “potent glucose-lowering effects towards near-normal ranges,” and also induces significant weight loss in people with type 2 diabetes, say the SURPASS-1 investigators.

SURPASS-2 trial results

Juan Pablo Frías

06-28-2021 | ADA 2021 | Conference coverage | Video

SURPASS-2: Tirzepatide versus semaglutide in people with type 2 diabetes

Juan Pablo Frías explains the significance of the SURPASS-2 findings, in which the dual agonist tirzepatide provided superior glycemic control and weight loss to semaglutide.

Runners

06-26-2021 | ADA 2021 | Conference coverage | News

Tirzepatide has efficacy edge over semaglutide in SURPASS-2

People with type 2 diabetes on metformin monotherapy have greater glycemic control improvement and weight reduction with tirzepatide than semaglutide, report the SURPASS-2 investigators.

SURPASS-3 trial results

Francesco Giorgino

06-27-2021 | ADA 2021 | Conference coverage | Video

SURPASS-3: Tirzepatide versus insulin degludec in type 2 diabetes

Francesco Giorgino discusses the advantages of tirzepatide over insulin degludec revealed in the SURPASS-3 findings for people requiring an injectable therapy for type 2 diabetes.

06-26-2021 | ADA 2021 | Conference coverage | News

SURPASS-3: Tirzepatide proves better option than degludec for type 2 diabetes

The SURPASS-3 findings show that people with type 2 diabetes can obtain better glycemic control with tirzepatide than insulin degludec, while losing rather than gaining weight.

SURPASS-4 trial results

Stefano Del Prato

10-22-2021 | Tirzepatide | Video

SURPASS-4: Tirzepatide as an alternative to insulin glargine in type 2 diabetes

Stefano Del Prato discusses the advantages of tirzepatide over insulin glargine for people with type 2 diabetes, and how the SURPASS-4 findings fit with those of the rest of the clinical trial program (7:42).

Woman applying diabetes medicine injection into her belly

10-19-2021 | Tirzepatide | News

Tirzepatide preferable to glargine when OADs fail in SURPASS-4

Tirzepatide provides better glucose control than insulin glargine in people with type 2 diabetes taking multiple oral antidiabetes medications, report the SURPASS-4 investigators in The Lancet.

SURPASS-5 trial results

Michelle Welch

06-29-2021 | ADA 2021 | Conference coverage | Video

SURPASS-5: Tirzepatide in people with insulin-dependent type 2 diabetes

Michelle Welch discusses the positive glycemic and weight loss findings for tirzepatide versus placebo in people with insulin-dependent type 2 diabetes in SURPASS-5.

06-27-2021 | ADA 2021 | Conference coverage | News

SURPASS-5: Glycemic, weight benefits of tirzepatide in insulin-dependent type 2 diabetes

People with insulin-dependent type 2 diabetes significantly improve their glycemic control, lose weight, and require less insulin if they also have a weekly injection of tirzepatide, show the SURPASS-5 findings.

At a glance

A quick guide to the SURPASS and SURMOUNT trials

Tirzepatide (formerly known as LY3298176) is a novel glucose-lowering medication that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.

View the quick guide here